DiaMedica Therapeutics Management
Management criteria checks 3/4
DiaMedica Therapeutics' CEO is Rick Pauls, appointed in Jan 2010, has a tenure of 16.25 years. total yearly compensation is $2.73M, comprised of 23.6% salary and 76.4% bonuses, including company stock and options. directly owns 0.13% of the company’s shares, worth $423.90K. The average tenure of the management team and the board of directors is 4.2 years and 3.2 years respectively.
Key information
Rick Pauls
Chief executive officer
US$2.7m
Total compensation
| CEO salary percentage | 23.65% |
| CEO tenure | 16.3yrs |
| CEO ownership | 0.1% |
| Management average tenure | 4.2yrs |
| Board average tenure | 3.2yrs |
Recent management updates
Recent updates
Preeclampsia Breakthrough Potential And Strong Cash Runway Will Support Future Value Creation
Catalysts About DiaMedica Therapeutics DiaMedica Therapeutics is a clinical stage biopharmaceutical company focused on developing DM199, a KLK1 protein therapy, for vascular conditions such as preeclampsia, fetal growth restriction and acute ischemic stroke. What are the underlying business or industry changes driving this perspective?
Preeclampsia And Stroke Programs Will Drive Long Term Potential For This Biotech
Catalysts About DiaMedica Therapeutics DiaMedica Therapeutics is a clinical stage biopharmaceutical company focused on developing DM199, a recombinant KLK1 therapy, for vascular conditions such as preeclampsia, fetal growth restriction and acute ischemic stroke. What are the underlying business or industry changes driving this perspective?Here's Why We're Not Too Worried About DiaMedica Therapeutics' (NASDAQ:DMAC) Cash Burn Situation
Dec 18
We Think DiaMedica Therapeutics (NASDAQ:DMAC) Can Afford To Drive Business Growth
Apr 23Here's Why We're Not Too Worried About DiaMedica Therapeutics' (NASDAQ:DMAC) Cash Burn Situation
Nov 23Here's Why We're Not Too Worried About DiaMedica Therapeutics' (NASDAQ:DMAC) Cash Burn Situation
May 16We're Hopeful That DiaMedica Therapeutics (NASDAQ:DMAC) Will Use Its Cash Wisely
Jan 12FDA puts DiaMedica's phase 2/3 trial for its stroke treatment DM199 on clinical hold
Jul 06We're Not Very Worried About DiaMedica Therapeutics' (NASDAQ:DMAC) Cash Burn Rate
Jun 16We're Hopeful That DiaMedica Therapeutics (NASDAQ:DMAC) Will Use Its Cash Wisely
Jan 04DiaMedica: Proven Stroke Drug In Asia, Headed To The U.S.
Nov 05We Think DiaMedica Therapeutics (NASDAQ:DMAC) Can Afford To Drive Business Growth
May 01CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Dec 31 2025 | US$3m | US$645k | -US$33m |
| Sep 30 2025 | n/a | n/a | -US$32m |
| Jun 30 2025 | n/a | n/a | -US$30m |
| Mar 31 2025 | n/a | n/a | -US$27m |
| Dec 31 2024 | US$2m | US$593k | -US$24m |
| Sep 30 2024 | n/a | n/a | -US$22m |
| Jun 30 2024 | n/a | n/a | -US$20m |
| Mar 31 2024 | n/a | n/a | -US$19m |
| Dec 31 2023 | US$1m | US$562k | -US$19m |
| Sep 30 2023 | n/a | n/a | -US$18m |
| Jun 30 2023 | n/a | n/a | -US$17m |
| Mar 31 2023 | n/a | n/a | -US$15m |
| Dec 31 2022 | US$1m | US$523k | -US$14m |
| Sep 30 2022 | n/a | n/a | -US$13m |
| Jun 30 2022 | n/a | n/a | -US$14m |
| Mar 31 2022 | n/a | n/a | -US$13m |
| Dec 31 2021 | US$1m | US$477k | -US$14m |
| Sep 30 2021 | n/a | n/a | -US$15m |
| Jun 30 2021 | n/a | n/a | -US$14m |
| Mar 31 2021 | n/a | n/a | -US$13m |
| Dec 31 2020 | US$878k | US$455k | -US$12m |
| Sep 30 2020 | n/a | n/a | -US$11m |
| Jun 30 2020 | n/a | n/a | -US$10m |
| Mar 31 2020 | n/a | n/a | -US$10m |
| Dec 31 2019 | US$2m | US$420k | -US$11m |
Compensation vs Market: Rick's total compensation ($USD2.73M) is about average for companies of similar size in the US market ($USD2.40M).
Compensation vs Earnings: Rick's compensation has increased whilst the company is unprofitable.
CEO
Rick Pauls (54 yo)
Mr. Dietrich John Pauls, also known as Rick, MBA has been Chief Executive Officer and President of DiaMedica Therapeutics Inc. since January 2010 and has been its Director since April 2005. Mr. Pauls was a...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| President | 16.3yrs | US$2.73m | 0.13% $ 423.9k | |
| CFO & Corporate Secretary | 8yrs | US$1.23m | 0.060% $ 199.6k | |
| Chief Medical Officer | less than a year | US$2.10m | no data | |
| Chief Technology Officer | 2.6yrs | no data | no data | |
| Chief Commercial Officer | 4.2yrs | no data | no data |
Experienced Management: DMAC's management team is considered experienced (4.2 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| President | 21yrs | US$2.73m | 0.13% $ 423.9k | |
| Independent Chairman | 10.5yrs | US$199.90k | 0.026% $ 88.1k | |
| Independent Director | 15.7yrs | US$148.42k | 0.63% $ 2.1m | |
| Independent Director | 2.9yrs | US$143.26k | 0.031% $ 103.6k | |
| Independent Director | 1.2yrs | US$358.27k | no data | |
| Independent Director | 3.1yrs | US$141.57k | no data | |
| Member of Stroke Advisory Board | 3.3yrs | no data | no data | |
| Member of Stroke Clinical Advisory Board | no data | no data | no data | |
| Independent Director | 4.8yrs | US$145.97k | 0.083% $ 275.7k | |
| Member of the Stroke Advisory Board | 2yrs | no data | no data | |
| Member of Stroke Clinical Advisory Board | no data | no data | no data | |
| Member of Preeclampsia Scientific Advisory Board | 1.3yrs | no data | no data |
Experienced Board: DMAC's board of directors are considered experienced (3.2 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/04/10 08:51 |
| End of Day Share Price | 2026/04/10 00:00 |
| Earnings | 2025/12/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
DiaMedica Therapeutics Inc. is covered by 13 analysts. 5 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Joshua Schimmer | Cantor Fitzgerald & Co. |
| Kyle Bauser | Colliers Securities |
| Chase Knickerbocker | Craig-Hallum Capital Group LLC |